Capricor shares skyrocket as FDA agrees to review new Duchenne drug data

Capricor Therapeutics’ shares jumped more than 100% in premarket after the U.S. health regulator indicated it is willing to review new data for its experimental Duchenne muscular dystrophy drug. The update is a meaningful positive catalyst for potential regulatory progress and risk reduction ahead of further trial/filing milestones.

Analysis

Capricor Therapeutics’ shares jumped more than 100% in premarket after the U.S. health regulator indicated it is willing to review new data for its experimental Duchenne muscular dystrophy drug. The update is a meaningful positive catalyst for potential regulatory progress and risk reduction ahead of further trial/filing milestones.